Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2021
Source ID
10.1016/j.urolonc.2021.03.004

Entities

People

  • Ali Raza Khaki
  • John L. Gore
  • Petros Grivas
  • Richard E Nelson
  • Sapna Kaul
  • Stephen B Williams
  • Yong Shan

Organizations

  • National Cancer Institute
  • United States Department of Defense